Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rapid response to trastuzumab emtansine in a patient with HER2-driven lung cancer.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Apr 2015

Weiler Daniela, Diebold Joachim, Strobel Klaus, Aebi Stefan, Gautschi Oliver

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Antibodies, Monoclonal, Humanized
Share to DNA, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to In Situ Hybridization

Share to Nucleic Acid Amplification Techniques

Share to Positron-Emission Tomography

Share to Receptor, ErbB-2

Share to Trastuzumab

Source

Identifiers

PMID: 25789838
DOI: 10.1097/JTO.0000000000000424

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rapid response to trastuzumab emtansine in a patient with HER2-driven lung cancer.PMID 25789838Read ↗

Impressive Response to Tyrosine Kinase Inhibitors in a Patient with Respiratory Failure for EGFR-Mutated Metastatic Lung Cancer.Semantic proximity Read ↗

HER2 Mutations in Non–Small-Cell Lung Cancer Can Be Continually TargetedSemantic proximity Read ↗

Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations.Semantic proximity Read ↗

Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial.Semantic proximity Read ↗

HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer.Semantic proximity Read ↗

First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trialSemantic proximity Read ↗

Ado-trastuzumab emtansine in the treatment of lung adenocarcinoma with ERBB2 mutation: a case report and literature review.Semantic proximity Read ↗

Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial.Semantic proximity Read ↗

Dramatic Response to Pyrotinib and T-DM1 in HER2-Negative Metastatic Breast Cancer With 2 Activating HER2 Mutations.Semantic proximity Read ↗

Successful Rechallenge of Trastuzumab Deruxtecan After Drug-Induced Interstitial Lung Disease in a NSCLC With HER2 Mutation: A Case ReportSemantic proximity Read ↗

Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers.Semantic proximity Read ↗

Successful Treatment of Non-Small Cell Lung Cancer With Erlotinib Throughout Pregnancy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.